Updated 04:19 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,873.60 -0.33% CL 88.49 -0.08% BTC 64,896.46 +1.20%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,874 −0.33% BTC $64,896 +1.20% VIX 19.30 +3.21% latest tape · as of 04:19 UTC
The Screen · Basic Materials · Chemicals

Westlake Chemical Partners LP

WLKP · the NYSE · USD · Market cap $739M

Westlake Chemical Partners LP acquires, develops, and operates ethylene production facilities and related assets in the United States.

Not yet scored
21.20 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price21.20 USD at the 13 Nov 2026 close
  • Fair value20.83. Our model only; only one analyst covers it, too few to cross-check it.
  • Our value readFair vs our fair value, as of 13 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans to puts (put/call 3.42)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $20.83 to $23.95, base estimate $20.83 (screen dated 2026-11-13).

Current read
Accumulation ?
Fair · screened 2026-11-13
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 3.42, read 2026-11-15
  • Ethical screen not yet scored
Price21.20 USD
Fair value20.83Our model only; only one analyst covers it, too few to cross-check it.
Ethical score70.0/100
Value readFairas of 13 Nov 2026
Our investment reviews on this name
2026-11-11Read Accumulation21.37-0.8% to today Markdown gives way to Accumulation while volume is distributing
2026-09-17Read Markdown21.73-2.4% to today ✓Distribution gives way to Markdown
2026-08-18Read Distribution21.67-2.2% to today ✓Markup gives way to Distribution after a 7% slide in 7 weeks
2026-07-02Read Markup23.33-9.1% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Westlake Chemical Partners LP holds its Accumulation at $21.20. Consolidating, no directional conviction, held for 149 days.

As held on the ledger · 2026-11-13
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 149 days
Price at the screen$21.20
Valuation12.78 trailing · 11.32 forward price to earnings
Values screenNot scored · score 70.0
Beta0.50
The Workings

Five Screens, Shown in Full

This security has not been fully scored against the values screen yet.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 31.81% Below 33% Interest-bearing debt is just 31.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 4.25% Below 49% Money owed to the company is 4.2% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

The Read, in Plain English

Westlake Chemical Partners LP clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Westlake Chemical Partners LP clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Westlake Chemical Partners LP clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Our model only; only one analyst covers it, too few to cross-check it.

Our analysis reads Fair vs our fair value, as of 13 Nov 2026: it trades above our $20.83 fair value estimate.

How a fair value is estimated: discounted cash flow (DCF).

20.83Conservative20.83Base case23.95Growth case 21.20Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 1.8% above the base estimate.

Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $20.83, with a range of $20.83 to $23.95, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business. At the screened price it sits 2% above our $20.83 fair value: priced for the quality, not a bargain.

The fundamentals · plain-English read
Forward P/E11.3xreasonably valued
Trailing P/E12.8xreasonably valued
EPS, trailing1.64
EPS, forward1.85
Revenue growth+0.0%revenue is shrinking
Profit margin4.7%barely profitable
Return on equity41.8%an exceptional return on shareholder capital
FCF yield37.20%
Dividend yield8.28%
Debt to equity0.52moderate, manageable leverage
Current ratio3.44comfortably covers its short-term bills
Beta0.50barely tracks the market's swings
Short interest, float0.01%
52-week range17.75 - 23.88
Market cap$739M

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

WLKP trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-11 Accumulation · changed $21.37 -1.9% Entry 17

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26.

2026-11-04 Markdown $21.78 +2.4% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Markdown $21.26 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-02 Markdown $21.26 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Markdown $21.26 +0.5% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Markdown $21.15 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Markdown $21.15 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Markdown $21.15 +0.9% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Markdown $20.96 +0.6% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Markdown $20.84 -1.7% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 7%. The street (2 analysts) rates it none, with a mean price target of $26.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on WLKP

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in WLKP's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.25 +0.2% $0.47 $1,022 +2.2%
2 months $22.21 +4.8% $0.47 $1,070 +7.0%
3 months $22.28 +4.5% $0.47 $1,066 +6.6%
6 months $18.91 +23.1% $0.94 $1,281 +28.1%
1 year $20.38 +14.2% $1.88 $1,235 +23.5%
2 years $19.14 +21.6% $3.77 $1,413 +41.3%
3 years $17.12 +35.9% $5.65 $1,689 +68.9%
5 years $18.01 +29.3% $9.42 $1,815 +81.5%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever WLKP does next, these words stay.

Westlake Chemical Partners LP · WLKP · Accumulation · $21.20
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.